Form 4: Orchestra BioMed CFO's Tax Withholding on RSU Vesting

Orchestra BioMed's CFO, Andrew Taylor, reported a disposition of 8,670 shares for tax withholding related to restricted stock unit vesting.

Summary

• Andrew Lawrence Taylor, Chief Financial Officer of Orchestra BioMed Holdings, Inc. (OBIO), reported a transaction on December 10, 2025.
• The transaction involved the disposition of 8,670 shares of common stock, par value $0.0001 per share, at a price of $4.67 per share.
• This disposition was due to the withholding of shares by the issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
• No shares were sold in the open market as a result of the vesting of these restricted stock units and the satisfaction of tax withholding obligations.
• Following this reported transaction, Andrew Taylor beneficially owns 454,945 shares of common stock directly.

Sentiment

Score: 5

Explanation: Neutral. This is a routine, non-discretionary transaction for tax purposes related to executive compensation, not indicative of positive or negative sentiment towards the company's prospects or operational performance.

Future Outlook

This Form 4 filing reports a historical transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This specific insider transaction is a routine event related to executive compensation and does not provide broader insights into industry trends or competitive dynamics.

Stakeholder Impact

• Minimal direct impact on shareholders as this is a non-discretionary tax-related transaction and not an open market sale.
• Confirms the ongoing executive compensation structure involving restricted stock units for key personnel.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary disposition of shares by the CFO for tax withholding purposes upon the vesting of restricted stock units. It does not reflect a discretionary sale or purchase based on new information about the company's performance or outlook, and therefore does not provide a basis for changing an existing investment thesis. The transaction is an expected part of executive compensation.

Keywords

Orchestra BioMed, OBIO, Form 4, Insider Transaction, CFO, Andrew Taylor, Restricted Stock Units, RSU Vesting, Tax Withholding, Beneficial Ownership